Literature DB >> 24463211

The myelodysplastic syndrome-comorbidity index provides additional prognostic information on patients stratified according to the revised international prognostic scoring system.

Esther Zipperer1, Nina Tanha, Corinna Strupp, Andrea Kündgen, Kathrin Nachtkamp, Judith Neukirchen, Barbara Hildebrandt, Rainer Haas, Norbert Gattermann, Ulrich Germing.   

Abstract

Entities:  

Keywords:  IPSS-R prognosis; MDS-CI; comorbidities; myelodysplastic syndromes

Mesh：

Year:  2014        PMID： 24463211      PMCID： PMC3943327          DOI： 10.3324/haematol.2013.101055

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  11 in total

1.  Revised international prognostic scoring system for myelodysplastic syndromes.

Authors:  Peter L Greenberg; Heinz Tuechler; Julie Schanz; Guillermo Sanz; Guillermo Garcia-Manero; Francesc Solé; John M Bennett; David Bowen; Pierre Fenaux; Francois Dreyfus; Hagop Kantarjian; Andrea Kuendgen; Alessandro Levis; Luca Malcovati; Mario Cazzola; Jaroslav Cermak; Christa Fonatsch; Michelle M Le Beau; Marilyn L Slovak; Otto Krieger; Michael Luebbert; Jaroslaw Maciejewski; Silvia M M Magalhaes; Yasushi Miyazaki; Michael Pfeilstöcker; Mikkael Sekeres; Wolfgang R Sperr; Reinhard Stauder; Sudhir Tauro; Peter Valent; Teresa Vallespi; Arjan A van de Loosdrecht; Ulrich Germing; Detlef Haase
Journal:  Blood       Date:  2012-06-27       Impact factor: 22.113

2.  Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells.

Authors:  S Geyh; S Oz; R-P Cadeddu; J Fröbel; B Brückner; A Kündgen; R Fenk; I Bruns; C Zilkens; D Hermsen; N Gattermann; G Kobbe; U Germing; F Lyko; R Haas; T Schroeder
Journal:  Leukemia       Date:  2013-03-29       Impact factor: 11.528

3.  Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome.

Authors:  Matteo G Della Porta; Luca Malcovati; Corinna Strupp; Ilaria Ambaglio; Andrea Kuendgen; Esther Zipperer; Erica Travaglino; Rosangela Invernizzi; Cristiana Pascutto; Mario Lazzarino; Ulrich Germing; Mario Cazzola
Journal:  Haematologica       Date:  2010-12-06       Impact factor: 9.941

4.  Evaluation of overall survival according to myelodysplastic syndrome-specific comorbidity index in a large series of myelodysplastic syndromes.

Authors:  Massimo Breccia; Vincenzo Federico; Giuseppina Loglisci; Adriano Salaroli; Alessandra Serrao; Giuliana Alimena
Journal:  Haematologica       Date:  2011-10       Impact factor: 9.941

5.  Proposals for the classification of the myelodysplastic syndromes.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1982-06       Impact factor: 6.998

6.  Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group.

Authors:  W R Sperr; F Wimazal; M Kundi; C Baumgartner; T Nösslinger; A Makrai; R Stauder; O Krieger; M Pfeilstöcker; P Valent
Journal:  Ann Oncol       Date:  2009-07-15       Impact factor: 32.976

7.  Undertreatment strongly decreases prognosis of breast cancer in elderly women.

Authors:  Christine Bouchardy; Elisabetta Rapiti; Gérald Fioretta; Paul Laissue; Isabelle Neyroud-Caspar; Peter Schäfer; John Kurtz; André-Pascal Sappino; Georges Vlastos
Journal:  J Clin Oncol       Date:  2003-08-11       Impact factor: 44.544

8.  Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes.

Authors:  Rong Wang; Cary P Gross; Stephanie Halene; Xiaomei Ma
Journal:  Leuk Res       Date:  2009-03-25       Impact factor: 3.156

9.  Proposed score for survival of patients with myelodysplastic syndromes.

Authors:  Wolfgang R Sperr; Michael Kundi; Friedrich Wimazal; Thomas Nösslinger; Anabel Schönmetzler-Makrai; Reinhard Stauder; Otto Krieger; Judith Neukirchen; Ulrich Germing; Michael Pfeilstöcker; Peter Valent
Journal:  Eur J Clin Invest       Date:  2013-09-18       Impact factor: 4.686

10.  The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome.

Authors:  Esther Zipperer; Daniela Pelz; Kathrin Nachtkamp; Andrea Kuendgen; Corinna Strupp; Norbert Gattermann; Rainer Haas; Ulrich Germing
Journal:  Haematologica       Date:  2009-03-31       Impact factor: 9.941
View more
  9 in total

1.  Integrating patient-centered factors in the risk assessment of MDS.

Authors:  Rena J Buckstein
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 2.  MDS prognostic scoring systems – past, present, and future.

Authors:  Brian A Jonas; Peter L Greenberg
Journal:  Best Pract Res Clin Haematol       Date:  2014-11-11       Impact factor: 3.020

3.  Assessing the Prognosis of Patients with Myelodysplastic Syndromes (MDS).

Authors:  Annika Kasprzak; Kathrin Nachtkamp; Norbert Gattermann; Ulrich Germing
Journal:  Cancers (Basel)       Date:  2022-04-12       Impact factor: 6.575

4.  Risk factors for cardiovascular disease mortality in patients with myelodysplastic syndromes: A nationwide, registry-based cohort study.

Authors:  Konstantinos Liapis; Georgios Vrachiolias; Vasileios Papadopoulos; Alexandra Kourakli; Athanasios G Galanopoulos; Menelaos Papoutselis; Sotirios G Papageorgiou; Panagiotis T Diamantopoulos; Vassiliki Pappa; Nora-Athina Viniou; Theodoros P Vassilakopoulos; Eleftheria Hatzimichael; Eleni Bouronikou; Maria Ximeri; Charalambos Pontikoglou; Panayiotis Panayiotidis; Stamatis Karakatsanis; Anna Vardi; Argiris Symeonidis; Ioannis Kotsianidis
Journal:  EJHaem       Date:  2020-07-01

5.  Prognostic Impact of Platelet-Large Cell Ratio In Myelodysplastic Syndromes.

Authors:  Qiuni Chen; Yue Chen; Yijing Zhang; Lijuan Zhang; Kankan Chen; Zhengmei He; Chunling Wang; Liang Yu
Journal:  Front Oncol       Date:  2022-04-01       Impact factor: 5.738

Review 6.  Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy.

Authors:  Olga Blau; Igor Wolfgang Blau
Journal:  Stem Cells Cloning       Date:  2014-12-04

7.  Gender disparity in the survival of patients with primary myelodysplastic syndrome.

Authors:  Fangfang Wang; Jun Ni; Lei Wu; Ying Wang; Bin He; Duonan Yu
Journal:  J Cancer       Date:  2019-01-30       Impact factor: 4.207

8.  [The prognostic significance of pretransplantation evaluation of IPSS-R and WPSS in patients with myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation].

Authors:  C Q Lu; C Hou; P Wang; L W Zhang; Y Fan; D P Wu; Y Xu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2022-03-14

Review 9.  Rethinking clinical trial endpoints in myelodysplastic syndromes.

Authors:  Mikkael A Sekeres; David P Steensma
Journal:  Leukemia       Date:  2019-01-30       Impact factor: 11.528
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.